Attila Jones

Attila Jones

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2024 in Science
Verified
Journal Article
Open access
EMEduardo A. Maury
Eduardo A. Maury
AJAttila Jones
Attila Jones
VSVladimir Seplyarskiy
Vladimir Seplyarskiy
TNThanh Thanh L. Nguyen
Thanh Thanh L. Nguyen
CRChaggai Rosenbluh
Chaggai Rosenbluh
ACAndrew Chess
Andrew Chess
Germline mutations modulate the risk of developing schizophrenia (SCZ). Much less is known about the role of mosaic somatic mutations in the context of SCZ. Deep (239×) whole-genome sequencing (WGS) of brain neurons from 61 SCZ cases and 25 controls postmortem identified mutations occurring during prenatal neurogenesis. SCZ cases showed increased somatic variants in open chromatin, with increased mosaic CpG transversions (CpG>GpG) and T>G mutations at transcription factor binding sites (TFBSs) overlapping open chromatin, a result not seen in controls. Some of these variants alter gene expression, including SCZ risk genes and genes involved in neurodevelopment. Although these mutational processes can reflect a difference in factors indirectly involved in disease, increased somatic mutations at developmental TFBSs could also potentially contribute to SCZ.

12 June 2023 in Movement Disorders
Verified
Journal Article
Closed access
GMGabriel Miltenberger-Miltenyi
Gabriel Miltenberger-Miltenyi
AJAttila Jones
Attila Jones
ATAmber M. Tetlow
Amber M. Tetlow
VCVasco A. Conceição
Vasco A. Conceição
JCJohn F. Crary
John F. Crary
RWRuth H. Walker
Ruth H. Walker

20 November 2023 in Scientific Data
Verified
Journal Article
Open access
PDF file
MGMcKinzie A. Garrison
McKinzie A. Garrison
YJYeongjun Jang
Yeongjun Jang
TBTaejeong Bae
Taejeong Bae
ACAdriana Cherskov
Adriana Cherskov
SESarah B. Emery
Sarah B. Emery
AAAlexij Abyzov
Alexij Abyzov
Somatic mosaicism is defined as an occurrence of two or more populations of cells having genomic sequences differing at given loci in an individual who is derived from a single zygote. It is a characteristic of multicellular organisms that plays a crucial role in normal development and disease. To study the nature and extent of somatic mosaicism in autism spectrum disorder, bipolar disorder, focal cortical dysplasia, schizophrenia, and Tourette syndrome, a multi-institutional consortium called the Brain Somatic Mosaicism Network (BSMN) was formed through the National Institute of Mental Health (NIMH). In addition to genomic data of affected and neurotypical brains, the BSMN also developed and validated a best practices somatic single nucleotide variant calling workflow through the analysis of reference brain tissue. These resources, which include >400 terabytes of data from 1087 subjects, are now available to the research community via the NIMH Data Archive (NDA) and are described here.

10 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
YWYifan Wang
Yifan Wang
TBTaejeong Bae
Taejeong Bae
JTJeremy Thorpe
Jeremy Thorpe
MSMaxwell A. Sherman
Maxwell A. Sherman
AJAttila Jones
Attila Jones
AAAlexij Abyzov
Alexij Abyzov
Post-zygotic mutations incurred during DNA replication, DNA repair, and other cellular processes lead to somatic mosaicism. Somatic mosaicism is an established cause of various diseases, including cancers. However, detecting mosaic variants in DNA from non-cancerous somatic tissues poses significant challenges, particularly if the variants only are present in a small fraction of cells. Here, the Brain Somatic Mosaicism Network conducted a coordinated, multi-institutional study to: (i) examine the ability of existing methods to detect simulated somatic single nucleotide variants (SNVs) in DNA mixing experiments; (ii) generate multiple replicates of whole genome sequencing data from the dorsolateral prefrontal cortex, other brain regions, dura mater, and dural fibroblasts of a single neurotypical individual; (iii) devise strategies to discover somatic SNVs; and (iv) apply various approaches to validate somatic SNVs. These efforts led to the identification of 43 bona fide somatic SNVs that ranged in variant allele fractions from ~0.005 to ~0.28. Guided by these results, we devised best practices for calling mosaic SNVs from 250X whole genome sequencing data in the accessible portion of the human genome that achieve 90% specificity and sensitivity. Finally, we demonstrated that analysis of multiple bulk DNA samples from a single individual allows the reconstruction of early developmental cell lineage trees. Thus, this study provides a unified set of best practices to detect somatic SNVs in non-cancerous tissues. The data and methods are freely available to the scientific community and should serve as a guide to assess the contributions of somatic SNVs to neuropsychiatric diseases.

9 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AJAttila Jones
Attila Jones
TLTina Loeffler
Tina Loeffler
EWEvan Wu
Evan Wu
VVVijay R. Varma
Vijay R. Varma
HIHae Kyung Im
Hae Kyung Im
MTMadhav Thambisetty
Madhav Thambisetty
Despite a growing body of evidence implicating genetic variants and proteins encoded by them with risk and pathogenesis of Alzheimer’s disease (AD), this knowledge has not been successfully translated into effective AD treatments. We integrated current genomic, transcriptomic and proteomic profiles of AD into a network pharmacology framework that leverages comprehensive gene-gene and drug-target interactions. This approach allowed us to screen 2,413 drugs for repurposing opportunities in AD. Computational validation and drug prioritization was followed by experimental validation in 33 cell culture-based phenotypic assays combined with Bayesian hypothesis testing. Our network-based screen rediscovered drugs in clinical trials for AD, providing computational validation. Besides many cancer drugs, the screen identified three drugs previously implicated in AD-related endophenotypes: the primary bile acid chenodiol, arundine (3,3’-diindolylmethane), and cysteamine. In analysis of results from culture-based phenotypic assays, large Bayes factors supported the hypothesized benefits of arundine and the chenodiol derivative, tauroursodeoxycholic acid (TUDCA), in amyloid- β clearance and release and neuroinflammation. Follow-up network analyses mechanistically implicated Regulator of G protein signaling 4 (RGS4) in the plausible therapeutic actions of arundine and TUDCA. A network pharmacology approach identified TUDCA and arundine as promising repurposing candidates in AD that rescue disease-relevant molecular phenotypes by acting on AD-associated genes through regulation of G protein signaling.